Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.4.0.3
Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Operating Costs and Expenses:    
General and administrative $ 2,426 $ 1,713
Research and development 8,155 6,494
Total Operating Costs and Expenses 10,581 8,207
Loss from Operations (10,581) (8,207)
Other Income (Expense):    
Change in fair value of warrant liability (498) (4,152)
Interest income 1 1
Total Other Income (Expense) (497) (4,151)
Net Loss (11,078) (12,358)
Net Loss Attributable to Non-controlling Interest (233) 0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries $ (10,845) $ (12,358)
Net Loss Per Share - Basic and Dilutive (in dollars per share) $ (0.12) $ (0.17)
Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares) 90,826,752 72,673,959